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The purpose of the study was to determine the efficacy and safety of docetaxel plus continuous infusion of 5-fluorouracil (5-FU) in
patients with metastatic breast cancer previously treated with anthracyclines. A total of 41 patients with histologically proven
metastatic breast cancer and performance status 0–2, who had received at least one anthracycline-containing regimen, received
docetaxel 85mgm
 2 followed by continuous infusion of 5-FU 750mgm
 2day
 1 for 5 days every 3 weeks for up to eight cycles. All
patients received corticosteroid premedication, but there was no prophylactic colony-stimulating factor support. The most frequent
metastatic sites were the liver (61%), bone (29%), and lung (29%). All 41 patients were assessable for toxicity and 30 were eligible
and assessable for efficacy. The objective response rate was 70.0% (95% CI: 53.6–86.4%) for the per protocol group and 53.7% (95%
CI: 38.4–68.9%) for the intent-to-treat (ITT) population. For the ITT population, median duration of response was 8.4 months (95%
CI: 6.7–12.2 months), median time to progression was 6.7 months (95% CI 5.5–8.6 months), and median survival was 17 months
(95% CI: 12.3–not recorded months). Grade 3/4 neutropenia occurred in 54% of patients, with febrile neutropenia in 24% of
patients and 5% of cycles, but infections were rare. Stomatitis was frequent, grade 3 in 24% of patients and grade 4 in one patient
(2%), but manageable. Diarrhoea was rare, grade 3 in 7% of patients and 1% of cycles. Other grade 3/4 nonhaematological toxicities
were infrequent. In conclusion, this docetaxel/5-FU regimen is highly active and well tolerated in patients with anthracycline-
pretreated metastatic breast cancer. The efficacy is particularly promising, as one-third of patients were either second-line and/or
anthracycline-resistant/refractory.
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Anthracycline-based chemotherapy regimens remain standard
first-line treatment for metastatic breast cancer. After anthracy-
clines (i.e., doxorubicin and epirubicin), taxanes are currently the
most widely administered agents for metastatic breast cancer.
Docetaxel (Taxotere
s), a semisynthetic taxane prepared from a
noncytotoxic precursor extracted from the needles of the European
yew tree Taxus baccata, is one of the most active chemotherapeutic
agents against metastatic breast cancer. As a single agent,
docetaxel has demonstrated advantages over three combination
regimens: mitomycin–C with vinblastine (Nabholtz et al, 1999),
methotrexate with 5-fluorouracil (5-FU) (Sjo ¨stro ¨m et al, 1998), and
5-FU with vinorelbine (Bonneterre et al, 1998) in patients with
metastatic breast cancer previously treated with anthracycline-
based chemotherapy. Notably, in the comparison with mitomycin-
C/vinblastine, docetaxel was associated with a significantly
improved tumour response, time to progression, and survival
(Nabholtz et al, 1999). Combinations of docetaxel with other
chemotherapeutic agents, including anthracyclines, cisplatin,
cyclophosphamide, 5-FU, and vinorelbine, are currently being
evaluated in patients with advanced breast cancer with the aims of
improving objective tumour response rates and prolonging
survival (Die ´ras et al, 1996; Khayat and Antoine, 1997; Nabholtz
et al, 1997).
5-Fluorouracil is an antimetabolite, which has demonstrated
significant antitumour activity both as a single agent and as a
component of FAC (5-FU, doxorubicin, cyclophosphamide), one of
the most active combination regimens currently used to treat
metastatic breast cancer (Crown, 1998). 5-Fluorouracil is a good
candidate to evaluate in combination with docetaxel, since both
agents are effective against metastatic breast cancer, but have
different mechanisms of action and tolerability profiles. Neutro-
penia is the principal toxicity associated with docetaxel, whereas
stomatitis and diarrhoea are frequent with 5-FU (Petit et al, 1999).
In a tumour-bearing mouse model, therapeutic synergy was
observed between docetaxel and 5-FU, and 70% of the highest
nontoxic dose of each agent could be administered in combination
without any additional toxicity (Bissery et al, 1995).
With the increasing use of anthracycline-based chemotherapy as
adjuvant therapy, as well as first-line chemotherapy against
metastatic breast cancer, patients are frequently exposed to high
cumulative doses of anthracyclines and are therefore at risk of
resistance and cardiotoxicity (Wood et al, 1994). The combination
of docetaxel with 5-FU may be particularly useful in patients
previously treated with anthracyclines (but naı ¨ve to either Received 20 May 2002; revised 25 March 2003; accepted 26 March 2003
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ldocetaxel or 5-FU). A phase I study (Lortholary et al, 2000)
established docetaxel 85mgm
 2 given as a 1-h infusion followed
by 5-FU 750mgm
 2day
 1 (as a 5-day continuous infusion) given
every 3 weeks as the recommended dose of the combination for
phase II evaluation in patients with metastatic breast cancer
previously treated with anthracyclines. The primary end point in
this phase II study was objective response rate. Time to
progression, survival, duration of response, and safety profile
were also assessed.
PATIENTS AND METHODS
This phase II multicentre study was performed at eight centres in
France between May 1998 and July 1999.
Patients
Women aged 18–75 years with metastatic breast cancer previously
treated with one anthracycline-containing chemotherapy regimen
were eligible for this study. Other eligibility criteria included
the following: histologically proven breast cancer, with at least
one bidimensionally measurable lesion; previous neoadjuvant
and/or adjuvant and/or palliative chemotherapy that included
an anthracycline; not more than one prior chemotherapy regimen
for metastatic disease; no prior exposure to either taxanes or
5-FU administered as a continuous infusion; World Health
Organization (WHO) performance status of 0, 1, or 2; life expectancy
412 weeks; not pregnant and using effective contraception if
of child-bearing potential, and normal organ function (i.e., normal
total bilirubin, alkaline phosphatase, and AST o2.5 times the
upper limit of normal, neutrophil count 41500ml
 1, platelets
4100000ml
 1, haemoglobin 410gdl
 1, creatinine level o1.5
times the upper limit of normal). Hormonal therapy was permitted
if it had been administered more than 4 weeks before study entry.
Patients were ineligible if they had inflammatory breast cancer,
any history or evidence of brain or leptomeningeal metastases,
concomitant severe medical or psychiatric illness, a prior history
of congestive heart failure or myocardial infarction within the
previous year, peripheral neuropathy or active infection. Patients
with concurrent or prior malignancies, with the exception of basal
cell carcinoma and/or cervical carcinoma in situ, were excluded
from the trial.
All patients provided written informed consent, and the study
protocol was approved by the local institutional review boards at
each participating centre.
Treatment plan
Patients received docetaxel (Taxotere
s; Aventis, Antony, France)
85mgm
 2 administered as a 1-h infusion immediately followed by
5-FU 750mgm
 2day
 1 as a continuous infusion (24-h continuous
ambulatory treatment) for 5 days. Corticosteroids (methylpredni-
solone 64mg per os) were started the evening before, the morning
before the docetaxel infusion and the next day, in all three oral
doses of steroids.
Treatment was repeated every 3 weeks if the neutrophil count
was 41500ml
 1, platelets 4100000ml
 1 and the patient had
recovered from all nonhaematologic toxicity. Prophylactic granu-
locyte colony-stimulating factor (G-CSF) was not allowed during
the first treatment cycle.
Toxicity evaluations were based on the National Cancer
Institute’s Common Toxicity Criteria (NCI-CTC). Adverse events
not included in the NCI-CTC toxicity scale (i.e., fluid retention,
nail disorders and asthenia) were graded as mild (grade 1),
moderate (grade 2), severe (grade 3), or life threatening (grade 4).
If febrile neutropenia occurred, the subsequent dose of docetaxel
was reduced to 75mgm
 2. Liver function tests were performed
during each treatment cycle. Patients were removed from the study
if the total bilirubin or AST had increased by more than 1.5-fold
and 2.5-fold, respectively, above the upper limits of normal and
had not returned to normal after a delay of 2 weeks. If grade 3
mucositis occurred, patients subsequently received prophylactic
treatment with bicarbonates and amphoteracin mouthwash. If
grade 3 mucositis persisted, subsequent doses of docetaxel and
5-FU were reduced to 75 and 500mgm
 2, respectively.
If there was an observable response to treatment, up to eight
cycles of chemotherapy were administered, but if the best response
was stable, disease treatment was stopped after six cycles. Treatment
continued until either: two cycles after a complete response was
achieved, disease progression, unacceptable toxicity, or the patient
or physician decided to stop. In case of progression, severe adverse
event or withdrawal of consent, treatment was stopped. In the event
of a confirmed complete response after 1 month, treatment
continuation was at the discretion of the physician.
Assessment of response and toxicity
Pretreatment evaluation included a medical history and physical
examination, complete blood cell count, serum biochemistry,
baseline assessment of symptoms, chest X-ray, computed tomo-
graphy of the chest and abdomen, bone scan, an electrocardio-
gram, and other investigations as clinically indicated.
Every two cycles, all disease sites were observed by the same
assessment methods, and after the treatment was discontinued,
disease sites were assessed every 3 months until disease progres-
sion. An independent, blinded radiologist reviewed tumour
response data. Complete response (CR) was defined as complete
disappearance of all evidence of disease and no new lesions or
disease-related symptoms for more than 4 weeks. Partial response
(PR) was defined as 450% decrease, vs baseline, in the sum of the
perpendicular diameters of all measurable lesions that lasted at
least 4 weeks, with no new lesions. Progressive disease was defined
as a 425% increase in the sum of the diameters of measurable
lesions vs the smallest sum observed (or vs baseline if no decrease
occurred), or appearance of any new lesion. Stable disease was
defined as a decrease of o50% or an increase of o25% in the sum
of the diameters of all measurable lesions.
The duration of PR was from the start of treatment until the first
documentation of disease progression or death from progression;
the duration of a CR was from the time it was first documented.
The time to progression was estimated from the start of treatment
to disease progression or death from progression. Overall survival
was measured from the time treatment started to date of death
resulting from any cause.
Statistical methods
The primary parameter in this phase II study was objective
response rate. Secondary parameters were time to progression,
survival, duration of response, and tolerability. The study aimed to
recruit 40 patients, of whom 35 would be eligible. The survival
distributions for duration of response, time to progression, and
overall survival were estimated using the Kaplan–Meier method
(Kaplan and Meier, 1958).
RESULTS
Patient characteristics
In all, 41 patients with metastatic breast cancer previously treated
with anthracycline-based chemotherapy were enrolled between
June 1998 and May 1999. Seven of these patients were considered
ineligible because they did not meet the predefined criteria:
inflammatory breast cancer and previous continuous 5-FU
chemotherapy (n¼1), no measurable metastatic disease (n¼1),
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lascites (n¼1), and more than two prior hormonotherapy and
chemotherapy regimens (n¼4). The median age was 53 years
(range, 35–73 years) and all but two of the patients had a WHO
performance status of 0 or 1 (Table 1). Approximately half of the
population had two or more organs involved, the most frequent
disease site being the liver.
All patients had received one previous chemotherapy regimen,
most commonly administered as either neoadjuvant or adjuvant
treatment or for metastatic disease. Two-thirds of the study
patients received the combination of docetaxel plus 5-FU as first-
line chemotherapy for metastatic disease, and in one-third it was
second-line chemotherapy. One-third of the population was
considered anthracycline-resistant (relapse within 1 year after
the end of adjuvant anthracycline-based regimen or progression
after response or stabilization for palliative treatment) and two
patients were anthracycline-refractory (progression on adjuvant
therapy or as a best response during palliative treatment).
Treatment administration
A total of 248 cycles of chemotherapy were administered during
the study. The median number of cycles per patient was 6 (range,
1–9). The median relative dose intensity per patient was 0.98
(range, 0.65–1.08) for docetaxel and 0.98 (range, 0.57–1.02) for
5-FU. Dose reductions were necessitated in 10 cycles of docetaxel
(haematological toxicities, n¼4; nonhaematological toxicities,
n¼1; haematological and nonhaematological toxicity, n¼3; other,
n¼2) and eight cycles of 5-FU (haematological toxicities, n¼1;
nonhaematological toxicities, n¼3; haematological and nonhae-
matological toxicity, n¼2; other, n¼2). The treatment was
stopped in case of progression, severe adverse in event or
withdrawl of consent (Table 2).
Response and survival
Responses to treatment are listed in Table 3. Two independent
radiologists reviewed efficacy data. In the intent-to-treat (ITT)
analysis, one patient (2%) achieved a CR and 21 (51%) a PR, giving
an objective response rate (ORR) of 53.7% (95% CI: 38.4–68.9%).
Nine patients were not evaluable for response for the following
reasons: nonevaluable disease (n¼6), withdrawal because of grade
4 thrombocytopenia after one cycle, withdrawal with grade 4
stomatitis after one cycle and withdrawal with grade 3 stomatitis
after one cycle. Disease stabilisation was observed in six patients
and the remaining four patients had progressive disease.
A total of 30 patients were both eligible and evaluable, and
objective response occurred in 21 of these patients (ORR 70.0%;
95% CI: 53.6–86.4%), including one CR.
Among the 16 anthracycline-resistant/refractory patients, objec-
tive response occurred in five patients, including one refractory
patient. The overall response rate in the 25 anthracycline-sensitive
patients was 68% (17 patients). Among the 27 patients receiving
first-line chemotherapy for metastatic disease, objective response
occurred in 15 (56%), and among the 14 patients receiving
docetaxel/5-FU as second-line treatment for metastatic disease,
objective response occurred in seven (50%).
At a median follow-up time of 13 months (range, 0.5–29.6
months), the median time to progression for the ITT population
was 6.7 months (95% CI: 5.5–8.6 months). The median duration of
response in responding patients was 8.4 months (95% CI: 6.7–12.2
months).
As of March 2003, the median overall survival (ITT population)
was 17.41 months (95% CI 11.99–28.28).
Table 1 Patient and disease characteristics at baseline
Patients
Characteristics n (%)
Number of patients 41
Median age in years (range) 53 (35–73)
WHO performance status
0 17 (41)
1 22 (54)
2 2 (5)
Number of organs involved
1 19 (46)
2 19 (46)
X3 3 (7)
Disease sites
Bone 12 (29)
Liver 25 (61)
Skin 4 (10)
Lung 12 (29)
Lymph node 6 (15)
Other 5 (12)
Intent of previous chemotherapy
Neoadjuvant and adjuvant 4 (10)
Neoadjuvant only 5 (12)
Adjuvant only 18 (44)
Neoadjuvant and adjuvant and metastatic 1 (2)
Adjuvant and metastatic 3 (7)
Metastatic 10 (24)
First-line metastatic 27 (66)
Second-line metastatic 14 (34)
Anthracycline resistant
a 14 (34)
Anthracycline refractory
b 2 (5)
aResistant¼relapse within 1 year after the end of adjuvant anthracycline-based
regimen or progression after response or stabilization for palliative treatment.
bRefractory¼progression on adjuvant therapy or as a best response during palliative
treatment.
Table 3 Response to treatment
ITT (n¼41) Per protocol (n¼30)
n (%) n (%)
CR 1 (2) 1 (3)
PR 21 (51) 20 (67)
ORR 22 (53.7) 21 (70)
Stable disease 6 (15) 6 (20)
Progressive disease 4 (10) 3 (10)
Not evaluable 9 (22) —
Table 2 Reasons for withdrawal
Patients
Characteristic n (%)
Number of patients 41
Reasons for stopping treatment
End of treatment (eight cycles received) 12 29
Adverse event 8 20
Progressive disease 12 29
Withdrawal consent 4 10
Stable disease (six cycles received) 1 2
Other
a 37
Death from progression (after one cycle) 1 2
aOther¼one patient¼complete response after six cycles (surgery: mastectomy);
one patient¼medullar compression after six cycles; one patient¼asthenia and
suspicion progressive disease.
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All 41 patients were assessable for toxicity. The most common
haematological adverse event was neutropenia, with grade 3 or 4
neutropenia occurring in half of the patients and one-quarter of
treatment cycles (Table 4). Grade 3 or 4 thrombocytopenia and
anaemia were rare, occurring in o1% of cycles. Febrile
neutropenia occurred in 10 patients (24%) but there were no
septic deaths. Nonhaematological toxicities are summarised in
Table 5. Asthenia occurred in more than half the population, but
was generally grade 1 or 2. Vomiting was generally mild, despite
the fact that patients did not receive any antiemetic premedication.
Stomatitis was almost universal, occurring at grade 1 or 2 in two-
thirds of the population and grade 3 in most of the remainder.
Severe diarrhoea was uncommon: only three patients experienced
grade 3 diarrhoea. Three-quarters of patients experienced grade 2
alopecia. Cutaneous adverse events were seen in 56% of patients,
mostly mild or moderate nonpruritic erythema. However, in two
patients, skin toxicity was severe and resulted in skin desquama-
tion, which necessitated reduction of the dosage of docetaxel in the
subsequent cycles. Nail disorder was infrequent and mild. Fluid
retention occurred in one-third of the patients, but was never
severe, and in two of these patients there was some evidence of
pleural effusion.
DISCUSSION
We performed a multicentre phase II trial of docetaxel 85mgm
 2
combined with 5-FU 750mgm
 2day
 1 by ambulatory continuous
infusion for 5 days, without G–CSF, in 41 patients with metastatic
breast cancer previously treated with anthracycline-based chemo-
therapy. A phase I study (Lortholary et al, 2000) had previously
established the recommended dose of these agents for phase II
evaluation in this clinical setting. As the use of anthracyclines as
adjuvant therapy and first-line treatment of metastatic disease
increases, so does the risk of resistance and cardiotoxicity (Wood
et al, 1994). The combination used in this study may offer promise
to patients previously treated with anthracyclines but naı ¨ve to
docetaxel or 5-FU. In this study, the use of docetaxel plus 5-FU
resulted in an ORR of 53.7% (95% CI: 38.4–68.9%) in the ITT
population. The median duration of response was 8.4 months and
median time to progression was 6.7 months. Among the 30 eligible
and evaluable patients, the ORR was 70.0% (95% CI: 53.6–86.4%).
The combination regimen was well tolerated. The main toxicities,
haematological and stomatitis, were manageable with dose
adjustment and supportive care. Mucositis is known to be
associated with 5-FU treatment, and is frequently observed with
other 5-FU-based combination regimens used to treat metastatic
breast cancer (Chevallier et al, 1990; Saphner et al, 1992; Carmo-
Pereira et al, 1993; Fine et al, 1994; Villalon et al, 1997).
The 85mgm
 2 dose of docetaxel determined for use in
combination with 5-FU is only slightly lower than that recom-
mended for single-agent chemotherapy (100mgm
 2). Single-agent
docetaxel has also shown activity against advanced breast cancer
at lower doses, with an ORR of 52 and 44% at doses of 75 and
60mgm
 2, respectively (Henderson, 1991; Die ´ras et al, 1996).
Several studies have shown that single-agent docetaxel is effective
against anthracycline-resistant metastatic breast cancer, achieving
objective response rates ranging from 53 to 57% (Ravdin
et al, 1995; Valero et al, 1995; Nabholtz et al, 1999). Although
patients in this study were not required to have anthracycline
resistance, all had been previously treated with at least one
anthracycline-based regimen. One–third of our study popula-
tion were either receiving second–line treatment and/or had
developed resistance, or were refractory, to anthracyclines. The
ORR in our study compares favourably with other taxane-based
combination regimens, including some taxane-anthracycline regi-
mens. A recent phase II study of docetaxel 60mgm
 2 plus
doxorubicin 60mgm
 2 plus G–CSF every 3 weeks in the first-line
treatment of 54 patients with metastatic breast cancer reported an
ORR of 57% (95% CI: 42–70%) in 51 evaluable patients (Sparano
et al, 2000).
There are relatively few completed phase II studies involving
docetaxel-based combination chemotherapy that do not contain an
anthracycline. One study that evaluated a combination of docetaxel
75mgm
 2 plus cisplatin 80mgm
 2 every 3 weeks in 38 patients
with anthracycline-resistant advanced breast cancer reported an
ORR of 36% (95% CI: 20–55%) (Spielmann et al, 1999). However,
almost all patients experienced severe neutropenia and one-
quarter developed febrile neutropenia. A higher response rate of
54% (95% CI: 40–67%) was achieved with the combination of
gemcitabine 900mgm
 2 on days 1 and 8 plus docetaxel
100mgm
 2 on day 8 plus G-CSF every 3 weeks in 52 patients
with anthracycline-pretreated metastatic breast cancer (Mavroudis
et al, 1999). Complete response occurred in seven patients (14%),
and responses were observed at all metastatic sites. This
combination was better tolerated, with a lower incidence of severe
haematological toxicity. The highest response rate occurred in a
Table 5 Incidence of nonhaematological toxicities
Patients (n¼41) Cycles (n¼248)
All Grade 3 Grade 4 All Grade 3 Grade 4
n (%) n (%) n (%) n (%) n (%) n (%)
Asthenia 24 (59) 4 (10) — 48 (19) 5 (2) —
Nausea 22 (54) 2 (5) — 50 (20) 3 (1) —
Vomiting 9 (22) 2 (5) — 11 (4) 2 (1) —
Stomatitis 38 (93) 10 (24) 1 (2) 108 (44) 12 (5) 1 (o1)
Fever 9 (22) 1 (2) 12 (5) 1 (o1) —
Nail toxicity 7 (17) — — 11 (4) — —
Infection 3 (7) — — 7 (2) — —
Cutaneous reaction 23 (56) 2 (5) — 83 (33) 2 (1) —
Oedema 13 (32) — — 35 (14) — —
Diarrhoea 18 (44) 3 (7) — 29 (12) 3 (1) —
Table 4 Incidence of Grade 3 or 4 haematological toxicities (%)
Patients (n¼41) Cycles (n¼248)
Neutropenia 54 24
Thrombocytopenia 2 o1
Anaemia 2 o1
Febrile neutropenia
a 24 5
aNeutropenia grade 4 with concomitant fever grade X38.51C and requiring IV
antibiotics and/or hospitalisation.
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 2 (day 1) with
weekly gemcitabine 800mgm
 2 (days 1, 8, and 15) in the second-
line treatment of 39 patients with metastatic breast cancer (33 of
whom had been treated with anthracyclines) (Laufman et al, 2001).
This treatment regimen resulted in an ORR of 79% (95% CI: 63–
91%). Haematological toxicity (predominantly neutropenia) was
significant, but manageable, and the median survival was 24
months (Laufman et al, 2001).
The results obtained with several other docetaxel-based
combination chemotherapy regimens (nonanthracycline) have
recently been presented as abstracts. Two phase II trials
investigated the combination of docetaxel plus vinorelbine in the
first- and second-line setting. Administration of vinorelbine
20mgm
 2 on days 1 and 8 plus docetaxel 85mgm
 2 every 3
weeks to 35 patients with chemotherapy-naı ¨ve advanced breast
cancer resulted in an ORR of 42.8% (95% CI: 26.5–60.5%) and was
associated with relatively low toxicity (Pectasides et al, 2000). A
slightly lower response rate (36.6%) was observed with docetaxel
60mgm
 2 plus vinorelbine 25mg/m
2, both administered on day 1
every 14 days to 49 patients with anthracycline-pretreated
metastatic breast cancer, but this dosage regimen was less well
tolerated (Gomez et al, 2000).
In other phase II studies on anthracycline-pretreated metastatic
breast cancer, docetaxel 75mgm
 2 plus cisplatin 75mgm
 2
produced an ORR of 52.7% (Pescia et al, 2000), while docetaxel
75mgm
 2 plus carboplatin AUC 5 resulted in an ORR of 40%
(Alberti, 2000). Taxanes (paclitaxel and docetaxel) enhance the
efficacy of capecitabine and 50-dFUrd in vivo, probably by
modulating dThdPase activity in tumour tissues. Synergistic
interaction between docetaxel and capecitabine was also demon-
strated in the animal model.
In addition, a recent phase III trial showed that docetaxel
75mgm
 2 combined with capecitabine 1250mgm
 2 (an oral
prodrug of 5-FU) is significantly superior to docetaxel mono-
therapy (100mgm
 2) in terms of ORR, TTP and survival with a
manageable toxicity profile in patients of anthracycline-pretreated
metastatic breast cancer. The ORR for the docetaxel–capecitabine
combination was 42% compared with 30%, P¼0.006 for docetaxel
monotherapy. Docetaxel/capecitabine therapy is an important
treatment option for women with anthracycline-pretreated MBC
(O’Shaughnessy et al, 2002).
In summary, the favourable response rate and tolerability profile
of the combination of docetaxel/5-FU evaluated in our study
suggest that this combination has clinically meaningful activity in
patients with MBC who have previously been treated with
anthracyclines. These results are very promising, as one-third of
the study population were either receiving second-line treatment
and/or were anthracycline-resistant/refractory. Further phase III
studies are now required to compare this combination of docetaxel
plus 5-FU continuous infusion with docetaxel alone and/or with
other combinations in order to determine the optimal treatment
for patients with anythracycline-pretreated MBC.
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